A randomized, double-blind, placebo-controlled phase 1b study evaluated the safety of the anti-oligomeric PRI-002 in 19 MCI or mild AD patients after 28 d of treatment. Overall, PRI-002 was well tolerated. While no biomarker changes or ARIA were detected, memory improved in the PRI-002 group.
- Janine Kutzsche
- Nicoleta Carmen Cosma
- Oliver Peters
